Using this approach, Miller et al[14] demonstrated that infusion of haploidentical NK cells after chemotherapy could induce remission in poor-prognosis AML patients, and remission was associated with KIR mismatch. The gene discussed is KIR3DL1; the disease is acute myeloid leukemia.